BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updates

PUBT · 1d ago
BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updates
  • BeOne highlighted a pipeline snapshot with 35+ clinical or commercial-stage assets across hematology, solid tumors, inflammation and immunology.
  • Sonrotoclax (BEQALZI) cited as approved in the U.S. for relapsed or refractory mantle cell lymphoma.
  • Sonrotoclax also cited as approved in China for relapsed or refractory mantle cell lymphoma, relapsed or refractory chronic lymphocytic leukemia.
  • Pipeline update flagged new Phase 1/Ib entries for BG-75202-102 in myeloid malignancies, BON-110-101 in solid tumors.
  • Update flagged BGB-43395-302 as entering a pivotal trial in first-line HR+/HER2- breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.